Blue Horseshoe Stocks: ITEK Recap, Options Ideas & More

Inotek Pharmaceutical Corp. ITEK

Our report for yesterday brought a couple of nice opportunities, with ITEK standing out as the most impressive. We caught this play on our routine morning scan, after noticing some abnormally elevated premarket activity. The company had released some information regarding its glaucoma treatment exiting Phase II studies and laying a strategic path for Phase III, and needless to say, it was very well-received.

This wasn’t a blink-and-you’ll-miss-it sort of move either, with just a small move up to start the session, ITEK traded sideways for most of the morning. Just prior to lunchtime is when we started to see the beginnings of an epic intraday run, especially for a stock in this price range.

From a low of  7.66, the stock exploded to reach a daily (and new annual) high of 16.75, standing as a single-session surge of 119%  The overall move as of this morning’s premarket high of 18.20 registers as an overnight increase of 138%  Cheers go out to any of our readers who caught our alert!

Inotek Pharmaceuticals Announces Positive End-of-Phase 2 Meeting with FDA and Phase 3 Development Strategy for Trabodenoson, a Novel Treatment for Glaucoma (Thu, Jul 23)


WindStream Technologies, Inc. WSTI

It was Tuesday’s Letter to Shareholders that caught our eye in the premarket news feed, causing us to raise a flag on WSTI that morning.

We’ve covered it every day since, and have been rewarded with incremental gains throughout, with the stock recording higher highs and higher lows each session. Yesterday, we witnessed an intraday run from .0172-.0244, which yielded the chance at gains of up to 42% on the day.

From our observed low on Tuesday (the 52-week low of .0085) we’ve now seen an overall jump in WSTI amounting to 187% in just three session’s time. Refer to the annotated chart below to evaluate WSTI’s chances of making further advances from this juncture.


Friday Options Ideas

If you recall last Friday, we came up huge with an alert on Weekly GOOG Calls.  We mentioned how time-decay at this point in the week begins to evaporate premiums in contracts with a weekly expiration, and generates a high-octane volatile environment where big gains are often there for the taking for those who can assume a higher-than-average risk.  A 694% intraday run from one of the sets of contracts we highlighted in that report was there to prove our point.

___

We’re going to venture a similar set of ideas this morning for Weekly AMZN Calls in the $575-595 range. The stock is gapping up hard this morning to the tune of 20%, thus we will have our eyes peeled for a classic dip-and-rip scenario.

___

We’re also going to put a marker flag on Weekly FB Calls from $96-50-97.50. The stock is rebounding off of a pullback over the past couple of days, after performing extremely well for the majority of this month.


Extended Watchlist:
AMDA, ACRX, CALA, ICLD, CRGP(news), HERO(52-wk lows)

Blue Horseshoe Stocks: Recap of Yesterday’s Huge Session

Our first order of business today will be to go over the wealth of premium gain opportunities contained in yesterday’s premarket report. We had not one, but three of our selections make major moves, not to mention a couple of other modest gainers.

Prima BioMed, Ltd. PBMD

Quickly shooting to the top of our watchlist was PBMD. Its performance was exhilarating to behold as the stock went on an absolute tear from a low of 2.08 on up to 6.48. It marked an epic intraday run which produced total possible gains on the order of 211%

The move occurred on monstrous volume to the tune of nearly 62X the 3-month average, and stemmed largely from some positive results on one of the company’s trial drugs, announced Tuesday. >> READ PR

With the kind of momentum we’ve witnessed building up in just a single session from PBMD, we’re very interested to continue to follow the price action. A significant dip-and-rip scenario could soon present itself.


IsoRay, Inc. ISR

We also tagged ISR in yesterday’s extended watchlist, and it too shot up rapidly with the help of optimistic results from one of its own drug trials. From an early low of 1.86, the stock ran up as high as 3.38, carving out an intraday rip of 82%

This morning, we saw ISR go as high as 4.00 in premarket trading, extending the overnight range on this play to an eyebrow-raising 115%

We’ll certainly be monitoring this stock as we cruise into week’s end. Like PBMD, we’ll be on the lookout for profit-taking to possibly put a dip-and-rip scenario into effect.


Holiday Island Holdings, Inc. HIHI

In our closing thought from yesterday’s report, we called attention to a massive one-third share reduction being enacted by HIHI, and were extremely pleased to have done so. From a low of .0015, the stock broke out to hit .00265; a healthy move totaling 76%

We then saw it pull back into the close, but we’re not finished monitoring the stock by any means. We caught wind of a promotion (in which we are not involved) going out on HIHI this morning, which could provide us with an impeccably-timed boost to extend our profits as we look to take them off the table.


In light of the monumental performances we’ve seen out of news-fueled pharma plays this week, we’ve dug up a few more this morning for us to pin to our watchlists:

Calithera Biosciences, Inc. CALA

Actinium Pharmaceuticals, Inc. ATNM

Ampio Pharmaceuticals, Inc. AMPE


Extended Watchlist:
NSPR, CTP, AVEO